LANGHORNE, Pa., May 21, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on Monday, June 2, 2025 from 1-9 p.m. CT. During the event Mr. Levy will participate in a fires ...

NEXGEL (NXGL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Valter Pinto - Managing DirectorAdam Levy - CEO, President & DirectorJoseph F. McGuire - CFOEric Ramos - Student Portfolio Manager Conference Call Participants Naz Rahman - AnalystNone - Analyst Operator Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's First Quarter twenty twenty five Financial Results Conference Call. I will now turn the call over to Walter ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41173 NexGel, Inc. (Exact name of registrant as specified in its charter) | Delaware | 26-4042544 | | - ...

Exhibit 99.1 NEXGEL Reports First Quarter 2025 Financial Results First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa. – May 13, 2025 – NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced ...

First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the ...

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p ...

Company Overview - NEXGEL, Inc. is a leading provider of medical and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications [1][3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades and offers brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] Upcoming Event - Adam Levy, the Chief Executive Officer of NEXGEL, will present at the Planet MicroCap Showcase: Vegas 2025, scheduled for April 22-24, 2025, at the Paris Hotel & Casino in Las Vegas, NV [1][2] - The presentation is set for April 23, 2025, at 9:30 a.m. PT, and there will be opportunities for one-on-one investor meetings [2]

Company Overview - NEXGEL, Inc. is a leading provider of medical and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications [1][3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades and offers brands such as SilverSeal®, Hexagels®, Turfguard®, Kenkoderm®, and Silly George® [3] Upcoming Event - Adam Levy, the Chief Executive Officer of NEXGEL, will present at the Planet MicroCap Showcase: Vegas 2025, scheduled for April 22-24, 2025, at the Paris Hotel & Casino in Las Vegas, NV [1][2] - The presentation is set for April 23, 2025, at 9:30 a.m. PT, and will take place in Track 4 - Loire [2] Strategic Relationships - NEXGEL has established strategic contract manufacturing relationships with leading consumer healthcare companies, enhancing its market presence and operational capabilities [3]

Operations and Capacity - The company operates a manufacturing facility of 13,500 square feet, currently at 15% to 20% capacity, with the potential to produce approximately 1.4 billion square inches of product annually at full capacity[18]. - The company maintains a policy of sufficient inventory of raw materials to prevent production disruptions, despite some components being sourced from sole suppliers[32]. - The company has a major customer accounting for approximately 20% of its revenue for the year ended December 31, 2023, with a long-standing relationship of over 15 years[35]. - The company has formed a joint venture with CG Laboratories, Inc., allowing for expanded delivery of finished goods to its customer base[15]. - The company has established a joint venture with CG Laboratories, Inc., named CG Converting and Packaging, LLC, which is located in Granbury, Texas, and allows for expanded delivery of finished goods to customers[117]. Product Development and Innovation - The company has developed the NEXDrape, a surgical drape designed for patients with impaired skin, and has filed for a patent under the Patent Cooperation Treaty[23]. - The NEXDrape aims to provide benefits such as no skin irritation and the ability to deliver antiseptic agents, addressing a significant and growing market[24]. - The company is also developing NEXDerm, an adhesive tape for securing medical devices, which is designed to be gentle on the skin and easy to remove[25]. - The company is pursuing custom and white label opportunities, allowing other brands to incorporate its hydrogel products into their offerings[21]. - The company has launched a new consumer product brand, Kenkoderm, in December 2023, and a third brand, Silly George, in May 2024, as part of its consumer product 'roll-up' strategy[121]. Financial Performance - Revenues for the year ended December 31, 2024, were $8,688 thousand, an increase of $4,599 thousand or 112.5% compared to $4,089 thousand in 2023, driven by sales growth in branded consumer products[125]. - Gross profit for 2024 was $2,748 thousand, up $2,374 thousand from $374 thousand in 2023, resulting in a gross profit margin of approximately 31.6% compared to 9.1% in the prior year[126]. - Total cost of revenues increased by $2,225 thousand or 59.9% to $5,940 thousand in 2024, primarily due to sales of branded consumer products[127]. - Selling, general and administrative expenses rose by $2,476 thousand or 66.1% to $6,224 thousand in 2024, largely due to increased advertising and marketing expenses[128]. - The net loss attributable to NexGel stockholders for 2024 was $3,281,000, slightly higher than the loss of $3,157,000 in 2023[170]. Cash Flow and Capital Management - Net cash used in operating activities was $3,867 thousand in 2024, compared to $3,236 thousand in 2023[139]. - Cash and cash equivalents at the end of 2024 were $1,807 thousand, down from $2,700 thousand at the end of 2023[139]. - The company expects to continue incurring losses in the near term, with future capital raises potentially necessary to fund acquisitions and growth initiatives[146]. - The company has entered into subscription agreements for the sale of units at $5.50 per unit, aiming to raise approximately $2.0 million for working capital and corporate purposes[185]. Regulatory and Compliance - The company is currently registered as a device manufacturer and distributor with the FDA and plans to register as a drug facility when required, ensuring compliance with regulatory standards[40]. - The company is subject to various environmental regulations and has made significant investments to comply, although future costs remain unpredictable[41]. - The company is subject to extensive governmental regulations, which can lead to fines, product recalls, and delays in new product approvals[67]. Market and Competition - The company faces intense competition in the hydrogel manufacturing industry, which may lead to pricing pressure and challenges in achieving market acceptance[60]. - The company recognizes the importance of market acceptance for its products, which is crucial for future success and financial performance[53]. - The company relies heavily on Amazon and Shopify for sales and distribution, indicating a significant dependency on these platforms for consumer product revenue[57]. Internal Controls and Governance - The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial statements[85]. - The company is in the process of designing and implementing measures to remediate identified material weaknesses in internal controls[86]. - The company has a history of operating losses and may struggle to raise needed capital, raising doubts about its ability to continue as a going concern[74]. Employee and Organizational Structure - As of December 31, 2024, the company had 19 full-time employees, with 14 involved in manufacturing and regulatory matters, highlighting a strong operational workforce[45]. - The company is committed to developing a high-performance culture and talent management strategy to support its strategic goals[46]. Intellectual Property and Strategic Partnerships - The company aims to protect its intellectual property through patents and trademarks, but enforcement may be difficult and costly[70]. - The company is seeking to enter into strategic partnerships to expand its business, but may face challenges in identifying and completing these partnerships[77].